This is a Phase I/II study for patients with solid tumors and renal cell carcinoma (RCC; for
the Phase II part). L19-IL2 is a tumor targeted immunocytokine constituted of a single chain
Fragment variable (scFv) format directed against the ED-B domain of fibronectin, one of the
most important markers for neoangiogenesis, and the human cytokine interleukin-2 (IL2).